Cardiology

HCA Healthcare Names Dr. Michael Cuffe Executive Vice President, Chief Clinical Officer

Monday, October 25, 2021 - 9:30pm

HCA Healthcare, Inc. (NYSE:HCA), one of the nations leading healthcare providers, today announced Michael Cuffe, MD, MBA, will become executive vice president and chief clinical officer of HCA Healthcare, effective January 1, 2022.

Key Points: 
  • HCA Healthcare, Inc. (NYSE:HCA), one of the nations leading healthcare providers, today announced Michael Cuffe, MD, MBA, will become executive vice president and chief clinical officer of HCA Healthcare, effective January 1, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20211025005784/en/
    HCA Healthcare Names Dr. Michael Cuffe Executive Vice President, Chief Clinical Officer (Photo: Business Wire)
    In his new role, Dr. Cuffe will be responsible for the companys clinical agenda.
  • Dr. Cuffe is a respected clinical and operational leader with a deep understanding of HCA Healthcares culture and operations, said Sam Hazen, chief executive officer of HCA Healthcare.
  • Prior to HCA Healthcare, Dr. Cuffe served as vice president for Ambulatory Services and chief medical officer for Duke University Health System.

ScottCare Signs Distribution Agreement With Ninety One, Expands Partnership

Monday, October 25, 2021 - 3:00pm

Bleron Baraliu, CEO of Ninety One, added, "This partnership combines ScottCare’s depth of experience and know-how with Ninety One's cloud-native, AI-driven innovative technology, and commitment to becoming the gold standard in cardiac RPM. Clients who choose our platform will leapfrog their peers in attaining the highest quality of patient care and unmatched operational efficiency -- reaping the benefits of digital health and Precision Medicine across several dimensions."

Key Points: 
  • ScottCare Cardiovascular Solutions ( www.scottcare.com ) announced that it has signed an agreement with Ninety One Holding, Inc. ( www.91.life ) to become a principal distributor for Ninety One's cloud software platform for cardiac implanted device monitoring, effectively expanding the partnership between the two firms.
  • Currently, ScottCares 24/7 remote cardiac monitoring service, Ambucor, utilizes the Ninety One platform to provide comprehensive, efficient patient data monitoring and management.
  • The expansion of this relationship will now allow ScottCare to offer Ninety Ones cloud platform directly to clinics that choose to monitor and manage patient data with their own staff.
  • ScottCare is committed to providing exceptional sales and service and will work closely with the Ninety One team on additional developments and enhancements to Ninety Ones cardiac monitoring platform.

Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Monday, October 25, 2021 - 2:05pm

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.

Key Points: 
  • Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.
  • Dr. Girgenti, a global leader in clinical research and drug development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller.
  • With the addition of Dr. Girgenti, Melinta expects to expand its world-class portfolio while continuing to drive operational excellence.
  • Dr. Girgenti joins Melinta from Magenta Therapeutics where he led clinical development programs for stem-cell mobilization and autoimmune diseases.

PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer

Monday, October 25, 2021 - 1:30pm

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (Veris) today announced the appointment of Silicon Valley technology executive Sunny Webb as Veris Chief Technology Officer and PAVmeds VP, Data & Analytics.

Key Points: 
  • PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (Veris) today announced the appointment of Silicon Valley technology executive Sunny Webb as Veris Chief Technology Officer and PAVmeds VP, Data & Analytics.
  • View the full release here: https://www.businesswire.com/news/home/20211025005453/en/
    Sunny Webb appointed as Chief Technology Officer for PAVmed Digital Health Subsidiary Veris Health (Photo: Business Wire)
    Ms. Webb will be joining other Veris leaders and guest panelists for the PAVmed digital health virtual investor event, Veris Heath: Bringing Digital Health to Cancer Care, to be held tomorrow, October 26, 2021, from 1:00 P.M. to 3:00 P.M. EDT.
  • I am very pleased to welcome Sunny Webb to the PAVmed and Veris team, said Lishan Aklog M.D., PAVmeds Chairman and Chief Executive Officer and Veris Executive Chairman.
  • Veris, a majority-owned subsidiary of PAVmed, acquired Oncodisc Inc., a digital health company with groundbreaking tools to improve personalized cancer care in May 2021.

Europe Deep Vein Thrombosis Market and Competitive Landscape Report 2021-2026: Pipeline, Epidemiology, Valuations, Forecasts, Drug Sales, Drug Forecasts, and Market Shares - ResearchAndMarkets.com

Monday, October 25, 2021 - 10:51am

The "Europe Deep Vein Thrombosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Deep Vein Thrombosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Deep Vein Thrombosis Market and Competitive Landscape 2021, provides comprehensive insights into Deep Vein Thrombosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Deep Vein Thrombosis treatment options, Deep Vein Thrombosis late-stage clinical trials pipeline, Deep Vein Thrombosis prevalence by countries, Deep Vein Thrombosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Deep Vein Thrombosis pipeline: Find out drugs in clinical trials for the treatment of Deep Vein Thrombosis by development phase 3, phase 2, by pharmacological class and company
    Deep Vein Thrombosis drugs: Identify key drugs marketed and prescribed for Deep Vein Thrombosis in the US, including trade name, molecule name, and company
    Deep Vein Thrombosis drugs sales: Find out the sales value for Deep Vein Thrombosis drugs by countries
    Deep Vein Thrombosis market valuations: Find out the market size for Deep Vein Thrombosis drugs in 2020 by countries.

Columbia China opens its third and largest hospital in Jiaxing, China

Saturday, October 23, 2021 - 9:11am

JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.

Key Points: 
  • JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.
  • The services provided at the Jiaxing Kaiyi Hospital include outpatient consultations, inpatient services, accident & emergency and health screening.
  • "With the opening of its third and largest hospital, Columbia China aims to deliver the highest level of healthcare quality, service and patient experience to the 5.5m population in Jiaxing," said Bee Lan Tan, President & Group CEO of Columbia China.
  • Columbia China is a privately-held Shanghai-based healthcare company jointly invested by Columbia Pacific Management (CPM) from the United States, Sheares Healthcare Group (SHEARES) from Singapore and Swire Pacific Limited from Hong Kong.

Columbia China opens its third and largest hospital in Jiaxing, China

Saturday, October 23, 2021 - 9:00am

JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.

Key Points: 
  • JIAXING, China, Oct. 23, 2021 /PRNewswire/ -- Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third & largest 500-bed multi-specialty hospital in Jiaxing, Zhejiang Province.
  • Jiaxing Kaiyi Hospital is licensed for 500 beds with a construction area of 112,000 square meters.
  • The services provided at the Jiaxing Kaiyi Hospital include outpatient consultations, inpatient services, accident & emergency and health screening.
  • "With the opening of its third and largest hospital, Columbia China aims to deliver the highest level of healthcare quality, service and patient experience to the 5.5m population in Jiaxing," said Bee Lan Tan, President & Group CEO of Columbia China.

Laboratoires Majorelle appoints Alexandre de Germay as Chief Executive Officer

Friday, October 22, 2021 - 4:03pm

PARIS, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Laboratoires Majorelle, a fast-growing French specialty pharma company focused on prescription and OTC products in women's health and urology, today announces the appointment of Alexandre de Germay as Chief Executive Officer.

Key Points: 
  • PARIS, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Laboratoires Majorelle, a fast-growing French specialty pharma company focused on prescription and OTC products in women's health and urology, today announces the appointment of Alexandre de Germay as Chief Executive Officer.
  • 9 billion across 300 assets and several therapeutic areas, including cardiology, transplant and established products.
  • During his tenure, Alexandrerefocused the organization toward assets and disease areas that delivered significant growth.
  • Olivier Bohuon, Chairman of Majorelle and Senior Adviser to EW Healthcare Partners, added: "On behalf of the Board and EW Healthcare Partners, I would like to warmly welcome Alexandre to Majorelle.

The Worldwide Cardiology IT Workflow Solutions Industry is Expected to Reach $1.6 Billion by 2027 - ResearchAndMarkets.com

Friday, October 22, 2021 - 1:30pm

The "Cardiology IT Workflow Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiology IT Workflow Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Cardiology IT Workflow Solutions estimated at US$980.8 Million in the year 2020, is projected to reach a revised size of US$1.6 Billion by 2027, growing at a CAGR of 7.2% over the period 2020-2027.
  • Cloud, one of the segments analyzed in the report, is projected to record 7.6% CAGR and reach US$991.7 Million by the end of the analysis period.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$355.3 Million by the year 2027 trailing a CAGR of 11% over the analysis period 2020 to 2027.

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF® (trifluridine/tipiracil) + bevacizumab in a 1st line setting for patients with unresectable mCRC non-eligible for intensive therapy

Friday, October 22, 2021 - 8:00am

SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.

Key Points: 
  • SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.
  • D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier.
  • The clinical value of LONSURF in its current indications remains unchanged, and the ongoing Phase III SUNLIGHT trial (LONSURF + bevacizumab versus LONSURF in 3rd line mCRC) is proceeding as planned.
  • SOLSTICE is an open-label, randomized, multicentre Phase III trial in 856 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy.